AzTrials
AzTrials

Ischemic StrokeWILLNCT07592962

Whole-life Investigation of Lishui Longevity

An observational study of Ischemic Stroke and Chronic Disease, run by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors. 2. Read more about this study

Who is it for?
Ages 30 to 80 years
Conditions the study is for
Ischemic Stroke, Chronic Disease, Cardiovascular
How many people
4,500 participants
Where
1 siteChina
Study dates
18 May 2026to 31 May 2036
How long will I take part?
10 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.

Who may be able to join

  • Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.

Who cannot join

  • Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jingping Sun, PhD contact

86-18504713450

lszxyysunjingping@yeah.net

China1 site, 1 recruiting

  • Lishui Central Hospital

    Lishui, Zhejiang, 323000

    Jingping Sun, PhD, 86-18504713450, lszxyysunjingping@yeah.net

    Recruiting

Other trials in China

About this study

Official title: Whole-life Investigation of Lishui Longevity Cohort Study

  1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.
  2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.
Read the detailed description

This project will establish a cohort related to stroke and tumors, with 4500 subjects selected from the 30-80-year-old urban-rural integrated population in Lishui City, covering both urban and rural residents in the urban-rural junction area of the region. This population, with diverse living habits and uneven access to medical resources, is a key group for the prevention and control of stroke and tumors, and its selection can reflect the epidemiological characteristics of the two diseases in Lishui.

To achieve the research goal, the subjects will be randomly divided into three groups for targeted detection, with specific schemes as follows:

Group A: Magnetic Resonance (MR) examination (focusing on the head and neck to identify cerebrovascular and tissue abnormalities) and methylation pan-cancer detection (non-invasive and high-sensitivity, used to screen for early methylation abnormal changes of tumor-related genes).

Group B: Methylation pan-cancer detection (consistent with Group A), Transcranial Doppler (TCD) examination (for intracranial hemodynamic monitoring), cervical ultrasound (for assessing cervical artery conditions), and Vibration-Controlled Transient Elastography (VCTE) examination (for detecting liver elasticity).

Group C: Physiological age methylation detection (evaluating the real physiological aging state through the methylation level of age-related CpG sites) and VCTE examination (consistent with Group B) to supplement liver function-related detection.

The core purpose of this project is to explore the three-dimensional distribution (time, place, and population distribution) of stroke and tumors in this population. Time distribution aims to explore the variation rules of incidence rates across different seasons, years, and age stages; regional distribution aims to analyze the differences in incidence rates among different urban-rural junctions and their correlation with environmental and medical resource factors; population distribution aims to identify high-risk groups by analyzing the differences in incidence rates among different genders, ages, living habits, and physiological aging states.

In addition, this project will clarify the correlation between each detection indicator and the two diseases, improve the construction of biological sample banks and databases, provide a scientific basis for establishing a community-hospital linked intervention system, thereby improving the early detection rate and intervention rate of diseases and protecting the health of residents

Keywords
acute ischemic stroke, carotid artery stenosis, Hepatic fibrosis
Medical subject headings
Ischemic Stroke, Chronic Disease, Carotid Stenosis, Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07592962
Study groupRoleWhat they receive
Cerebrovascular groupParticipants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases.
Tumor GroupThe tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population.
Epigenetic Age GroupThe epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence rate of stroke and tumors

    A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.

    Measured: From enrollment to the end of the 10-year follow-up period

Secondary outcomes (1)

  1. Unilateral carotid artery stenosis rate

    The degree of cervical vascular stenosis was detected and evaluated. The distribution of unilateral carotid artery stenosis rate (defined as stenosis degree >50%) was analyzed, which was calculated as the number of participants with carotid stenosis greater than 50% divided by the total screened population.

    Measured: From enrollment to the end of the 10-year follow-up period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2026
  2. Study start18 May 2026 (estimated)
  3. Primary completion31 May 2036 (estimated)
  4. Study completion31 May 2036 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
4,500 participants (estimated)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07592962
Sponsor's protocol ID
2026(I)164-01
Other IDs
Lishui Key R&D Project
Acronym
WILL
Status last verified
May 2026
First submitted
12 May 2026
Last updated
18 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The individual participant data (IPD) for this study will not be shared publicly due to concerns regarding participant privacy, data security, and the lack of an established data sharing agreement and platform. All data are stored and managed in accordance with applicable data protection regulations and institutional policies.

Publications

  • Pacinella G, Bona MM, Todaro F, Ciaccio AM, Daidone M, Tuttolomondo A. Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight. Int J Mol Sci. 2025 Oct 8;26(19):9801. doi: 10.3390/ijms26199801.

    PubMed 41097065

  • Wang J, Li Y, Qi L, Mamtilahun M, Liu C, Liu Z, Shi R, Wu S, Yang GY. Advanced rehabilitation in ischaemic stroke research. Stroke Vasc Neurol. 2024 Aug 27;9(4):328-343. doi: 10.1136/svn-2022-002285.

    PubMed 37788912

  • Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, Jiang Y, Guo Y, Zhang JH. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Ther. 2020 Dec;216:107695. doi: 10.1016/j.pharmthera.2020.107695. Epub 2020 Sep 28.

    PubMed 32998014

  • Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1.

    PubMed 39087353

  • Gilbertson RJ. Mapping cancer origins. Cell. 2011 Apr 1;145(1):25-9. doi: 10.1016/j.cell.2011.03.019.

    PubMed 21458665

  • Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024 Jul 26;25(15):8140. doi: 10.3390/ijms25158140.

    PubMed 39125710

  • Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14.

    PubMed 26667886

  • Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4.

    PubMed 28052979

  • Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C, Nishimura N, Schaffer CB, Whitehead SN, Black SE, Ostergaard L, Wardlaw J, Greenberg S, Friberg L, Norrving B, Rowe B, Joanette Y, Hacke W, Kuller L, Dichgans M, Endres M, Khachaturian ZS. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-984. doi: 10.1016/j.jalz.2019.06.001.

    PubMed 31327392

  • Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of Cognitive Decline After Incident Stroke. JAMA. 2015 Jul 7;314(1):41-51. doi: 10.1001/jama.2015.6968.

    PubMed 26151265

  • Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypponen E, Kuzma E, Llewellyn DJ. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019 Aug 6;322(5):430-437. doi: 10.1001/jama.2019.9879.

    PubMed 31302669

  • GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.

    PubMed 30879893

  • GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.

    PubMed 30496103

  • Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022 Feb;49(2):15. doi: 10.3892/ijmm.2021.5070. Epub 2021 Dec 8.

    PubMed 34878154

  • Pan Y, Jing J, Cai X, Wang Y, Wang S, Meng X, Zeng C, Shi J, Ji J, Lin J, Lyu L, Zhang Z, Mei L, Li S, Li S, Zhu W, Li H, Wei T, Wang Y. PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol. 2021 Mar;6(1):145-151. doi: 10.1136/svn-2020-000411. Epub 2020 Aug 30.

    PubMed 32863279

Questions about this trial

What is this clinical trial studying?

An observational study of Ischemic Stroke and Chronic Disease, run by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jingping Sun, PhD (86-18504713450, lszxyysunjingping@yeah.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence rate of stroke and tumors (time frame: From enrollment to the end of the 10-year follow-up period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07592962, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Whole-life Investigation of Lishui Longevity | AzTrials